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EXPERIMENTAL PROCEDURES THIOMAB Cloning, Expression, and Purification
To generate antibody expression vectors, the trastuzumab heavy and light chain sequences were modified to contain an upstream murine light chain secretory leader sequence (GeneArt) and ligated into the HindIII and XhoI restriction sites of pTT5. Site-specific Cys substitutions were introduced by overlap PCR and ligated into the HindIII and XhoI restriction sites of pTT5, and Cys mutations were numbered to be consistent with that previously reported (HC-A114C, LC-V205C, Fc-S396C). 1 DNA sequencing confirmed vector identity, and All antibodies were determined to be >95% pure by SDS-PAGE.
THIOMAB Conjugation Reactions and Plasma Stability
Conjugation reactions were carried out using 1 mg/mL antibody and 2 equivalents per labeling site of fluorescein-attached maleimide or sulfone linker in PBS (pH 7.4) at room temperature. Mild reduction was performed to free engineered Cys sulfhydryl groups blocked with either Cys or glutathione followed by diafiltration and oxidation prior to conjugation as described. 2 Reactions were allowed to proceed for 1, 2, 4, and 8 h. Unreacted compound was immediately removed by size exclusion column chromatography using a Micro Spin 6 column (Bio-Rad). Gel-loading solution containing 250 M tris(2-carboxyethyl)phosphine (TCEP) was added to each sample, and labeling was analyzed by SDS-PAGE using 10% NuPAGE Bis-Tris Gels (Life Technologies). Fluorescence and Coomassie stained gels were detected/quantified using a GelDoc XR Imaging System (Bio-Rad). Dye to antibody ratios were determined by absorbance measurements as described. 3 Conjugate plasma stability was assessed in triplicate as previously described. 3 In brief, fluorescently labeled THIOMABs were diluted into human plasma and incubated at 37 °C for the duration of the time course study. Time points were removed and stored at -80 °C, and then SDS-PAGE was performed as above.
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Analysis of HER2 Binding by Flow Cytometry
BT-474 cells were maintained in RPMI media 1640 with GlutaMAX (Gibco) containing 10% FBS and 1% Anti-Anti. 2 x 10 5 BT-474 cells were transferred to 1.5 mL Eppendorf tubes, and trastuzumab or THIOMAB conjugate was added at the indicated concentrations. Cells were incubated on ice for 1 h and washed three times with 500 L FACS buffer (PBS, 1% BSA, 0.01% NaN3, pH 7.4). AP-conjugated AffiPure F(ab')2 Fragment Goat Anti-Human IgG + IgM (H+L) secondary antibody (Jackson ImmunoResearch) was diluted 1:1,000 in 100 L FACS buffer and added to each sample for 1 h on ice. Samples were washed three times with 500 L FACS buffer and transferred to filter-top FACS tubes. Fluorescence was measured by flow cytometry (BD LSRII; BD Biosciences). For each sample, 30,000 live events were collected, and data were analyzed using FlowJo software (Tree Star, Inc.). All samples were tested in triplicate. blocked with 5% BSA in PBST for 1 h at 37 °C, and then washed 4 times with PBST. Next, antibody was added at 50 ng/mL in PBST with 1% BSA and incubated at 37 °C for 90 minutes.
Plates were washed 8 times with PBST. Goat Anti-Human Kappa AP conjugate (Bethyl Laboratories) was used as secondary antibody at a 1:1,000 dilution, which was then incubated at 37 °C for 1 hour and washed 4 times with PBST. Detection was performed at 405 nm after the addition of AP substrate (Sigma 104 phosphatase substrate).
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SELENOMAB Conjugation Reactions and Plasma Stability
The cloning, expression, and purification of R11-scFv-Fc-Sec and R11-scFv-Fc-stop antibody were performed as previously described. 4 Conjugation reaction were carried out using 4 µM (~0.5 mg/mL) R11-scFv-Fc-Sec or the negative control R11-scFv-Fc-stop and 40 µM fluorescein-attached maleimide or sulfone linker in 100 mM sodium acetate (pH 5.2) buffer in the presence of 20 µM dithiothreitol (DTT). The reactions were allowed to proceed for 1 h at room temperature. Unconjugated compounds were removed by 30-kDa cutoff centrifugal filter device (Millipore) and buffer-exchanged with PBS. The labeling was analyzed by SDS-PAGE under non-reducing conditions. Conjugate plasma stability was carried out as described for
THIOMABs.
Analysis of ROR1 Binding by Flow Cytometry
Human mantle cell lymphoma HBL-2 and chronic lymphocytic leukemia MEC-1 cells 1.6 1.9 HC-A114C 1.9 1.8 Table S1 . Summary of dye-to-antibody ratios (DAR) for THIOMABs labeled with maleimide or phenyloxadiazole sulfone linkers.
